post relates to the drug development timeline
Mass Balance – What, When, How? July 10, 2018 This “fishbone diagram”, shown by permission from Steven Baertschi (S. W. Baertschi et al, Trends in Analytical Chemistry 49 (2013) 126-136), lay’s out everything that could impact mass balance in a study of pharmaceutical stability and degradation. For our team, this is a problem solver’s map of the world: WHAT IS …
Neopharm Labs Acquires Averica Discovery November 3, 2016 Today Averica Discovery announced its acquisition by Neopharm Labs, an analytical testing lab based out of Quebec. Together the companies offer a full range of services that cover every stage of the drug development cycle including R&D, method development and validation, impurity isolation and profiling, stability testing …
Averica Answers: Can You Capture a .01% Impurity? Paul Lefebvre September 14, 2016 Averica Answers is a series of short videos that each tackle a question we are often asked. In this video, Paul Lefebvre discusses trace impurity isolation. “We do like to work with the customer to define a source of enriched material. Once …
Averica Answers: Can You Capture a 0.01% Impurity? Read More »
Averica Discovery Expands Capabilities and Capacity by 50% June 2, 2016 Enhances ability to supply early drug development programs while shorteningproject timelines MARLBOROUGH, MA, June 2, 2016 – Averica Discovery Services Inc., an analytical development contract research organization (CRO), today announced new hires and the acquisition of new equipment that significantly expands the Company’s capacity and …
Averica Discovery Expands Capabilities and Capacity by 50% Read More »
LabTube Meets March 22, 2016 LabTube houses a global of collection of scientific videos. Their “LabTube Meets” segment interviews scientists about research, trends and technical innovations. At Pittcon 2016 LabTube spoke with Mickey Rego about his presentation discussing ways prep chromatography can reduce risk in the early stages of drug development. Discover other great videos from Pittcon 2016, and scientists around …
InformEx: 5 min with Jeff Kiplinger 2016 February 2, 2016 AMONG THE CHALLENGES THE INDUSTRY FACES, WHICH DO YOU THINK ARE THE MOST PRESSING? These open ended questions always make me think in big picture terms, and for a scientist this means I’m probably beyond my expertise! I think we need to consider re-inventing an …
A Better Way to Look at Risk/Reward During Early Drug Development? Jeff Kiplinger October 16, 2015 How do you add value to a compound while maintaining cost effectiveness? The answer might depend on whether you’re part of the cautious development team, or hard-driving discovery team. In Pharmaceutical Online’s article, “Relative Cost Models: A Better Way …
A Better Way To Look At Risk/Reward During Early Drug Development? Read More »
August 26, 2015 Sometimes you know a lot about the genesis of pharmaceutical impurities, and in some cases you know very little. In either case, here are some things that you can try to make impurity isolation faster and improve the chances of success. Produce an enriched sample Whether from stress degradation, mother liquor, extraction, …
DeuteRx Research Stabilizing Thalidomide Enantiomers March 10, 2015 Our recent post about the history of chiral drugs and the thalidomide disaster was called to mind this week, as Andover (MA) based biotech DeuteRx published some interesting new work. The paper, in Proceedings of the National Academy of Sciences (PNAS), is entitled “Differentiation of antiinflammatory and antitumorigenic …
DeuteRx Research Stabilizing Thalidomide Enantiomers Read More »
Why Thalidomide Is Important to Chiral Separation September 12, 2014 The tragic history of the drug Thalidomide is familiar to many scientists in drug development – some of the more senior among us remember the disaster all too well. The problem with Thalidomide is one of the reasons chiral separation has become so important in …
Why Thalidomide Is Important to Chiral Separation Read More »
